Related Experiment Videos
[Botulinum toxin injection for neurogenic and no neurogenic bladder dysfunction]
Sergio Guzmán1, Patrick Honeck, Joachim Weiss
1Departamento de Urología, Universitätsklinikum Mannheim, Alemania. sergio.guzman@uni.ma.uni-heidelberg.de
Archivos Espanoles De Urologia
|November 22, 2005
Summary
Botulinum toxin A injections effectively treat neurogenic hyperreflexic bladder by improving capacity and reducing incontinence. Promising results were seen in idiopathic unstable bladder, but outcomes were poor for other bladder diseases.
Area of Science:
- Urology
- Pharmacology
Context:
- Botulinum toxin A (BTX-A) is increasingly used for detrusor muscle dysfunctions.
- Urologists are exploring BTX-A for various bladder conditions.
Purpose:
- To review the clinical experience with BTX-A in treating bladder dysfunction.
- To analyze treatment indications, clinical data, and urodynamics before and after BTX-A therapy.
Summary:
- BTX-A was administered to 28 patients with detrusor muscle dysfunction.
- Significant improvements in bladder capacity and reduced involuntary contractions were observed in neurogenic hyperreflexic bladder and idiopathic unstable bladder.
- Poor outcomes were noted in patients with other bladder diseases, often requiring surgical intervention.
Impact:
- BTX-A demonstrates efficacy in managing neurogenic hyperreflexic bladder, improving incontinence and bladder capacity.
- The therapy shows promise for idiopathic unstable bladder, though further research is needed.
- BTX-A is not recommended for other bladder diseases with anatomical changes.